{"id":68745,"date":"2026-02-20T17:22:38","date_gmt":"2026-02-20T17:22:38","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=68745"},"modified":"2026-10-15T10:34:00","modified_gmt":"2026-10-15T10:34:00","slug":"bpc-157","status":"publish","type":"product","link":"https:\/\/medsbase.com\/es\/product\/bpc-157\/","title":{"rendered":"BPC-157"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Respuesta r\u00e1pida \u2014 \u00bfQu\u00e9 es el BPC-157?<\/h3>\n<p style=\"margin: 0;\"><strong>BPC-157<\/strong> (Body Protection Compound 157) is a 15-amino-acid synthetic pentadecapeptide derived from a protective gastric protein. In published preclinical studies it has shown consistent effects on tendon, ligament, gut, muscle, and vascular tissue recovery via VEGF, nitric oxide, and growth-hormone-receptor signaling. Supplied in 2\u00a0mg to 10\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Qu\u00e9 obtienes con MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/es\/reviews\/\">opiniones de clientes<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Cada pedido est\u00e1 cubierto por nuestra <a href=\"https:\/\/medsbase.com\/es\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 si tu paquete no llega en 20 d\u00edas laborables, lo reenviamos.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especificaci\u00f3n<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalle<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">137525-51-0<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>F\u00f3rmula molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>62<\/sub>H<sub>98<\/sub>N<sub>16<\/sub>O<sub>22<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1419.55 Da<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Secuencia<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Polvo liofilizado (o seg\u00fan suministro)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificado por HPLC, COA bajo solicitud)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Almacenamiento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (refrigerador) para stock de trabajo; \u221220 \u00b0C para almacenamiento a largo plazo de viales sin abrir. Reconstituido: 2\u20138 \u00b0C, usar dentro de ~30 d\u00edas. Proteger de la luz. No congelar-descongelar la soluci\u00f3n reconstituida.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidad<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Agua bacteriost\u00e1tica (recomendada) o agua est\u00e9ril para periodos de uso m\u00e1s cortos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>\u00bfQu\u00e9 es el BPC-157?<\/h2>\n<p><strong>BPC-157<\/strong> es la abreviatura de <strong>Compuesto Protector Corporal 157<\/strong>, a 15-amino-acid synthetic pentadecapeptide originally isolated as a fragment of a larger protective protein found in human gastric juice. Unlike most peptides it is stable in gastric acid, which has made it a frequent subject of oral-administration studies in rodent models alongside the more common subcutaneous route. BPC-157 is one of the most widely studied healing peptides in the preclinical literature, with published work spanning tendon, ligament, gut barrier, skeletal muscle, bone, and vascular tissue. The peptide sequence is GEPPPGKPADDAGLV, molecular weight approximately 1,419\u00a0Da, empirical formula C<sub>62<\/sub>H<sub>98<\/sub>N<sub>16<\/sub>O<sub>22<\/sub>. It is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. For a deep-dive on mechanism, published trial detail, and dosing considerations, see our full <a href=\"https:\/\/medsbase.com\/es\/bpc-157-peptide-healing-recovery-guide\/\">BPC-157 guide<\/a>. <\/p>\n<h2>Mecanismo de acci\u00f3n: tres v\u00edas de curaci\u00f3n superpuestas<\/h2>\n<p>Lo que diferencia al BPC-157 de los p\u00e9ptidos de v\u00eda \u00fanica es su <strong>actividad simult\u00e1nea en tres rutas de se\u00f1alizaci\u00f3n distintas<\/strong>, each contributing to the observed tissue-recovery phenotype in published studies:<\/p>\n<ul>\n<li><strong>Angiog\u00e9nesis \/ regulaci\u00f3n al alza del VEGF<\/strong> \u2014 El BPC-157 regula al alza la expresi\u00f3n del receptor 2 del factor de crecimiento endotelial vascular (VEGFR2) en tejidos lesionados, promoviendo la formaci\u00f3n de nuevos capilares. Esto mejora la perfusi\u00f3n local en los sitios de reparaci\u00f3n, el paso limitante en la curaci\u00f3n de tendones, ligamentos y m\u00fasculos.<\/li>\n<li><strong>V\u00eda del \u00f3xido n\u00edtrico (NO)<\/strong> \u2014 El BPC-157 potencia la actividad de la \u00f3xido n\u00edtrico sintasa endotelial (eNOS) y protege el endotelio vascular contra el da\u00f1o oxidativo. En modelos de roedores con hipertensi\u00f3n portal, vasoconstricci\u00f3n sist\u00e9mica y \u00falceras g\u00e1stricas, este efecto es fundamental para la acci\u00f3n protectora del compuesto.<\/li>\n<li><strong>Regulaci\u00f3n al alza del receptor de hormona de crecimiento<\/strong> \u2014 El BPC-157 aumenta la expresi\u00f3n del receptor de hormona de crecimiento (GHR) en fibroblastos y tenocitos, mejorando la s\u00edntesis de col\u00e1geno tipo I. Se cree que este mecanismo subyace a las ganancias de resistencia en tendones observadas en modelos de transecci\u00f3n del ligamento colateral medial y del tend\u00f3n de Aquiles.<\/li>\n<\/ul>\n<p>Because these three pathways converge on tissue that has been injured, BPC-157 produces faster and more complete recovery than single-pathway interventions in the same models. It is also notably well tolerated across the range of published doses, with minimal off-target signaling reported in toxicology studies. <\/p>\n<h2>Published Evidence<\/h2>\n<p>BPC-157 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Recuperaci\u00f3n de lesiones en tendones y ligamentos<\/strong> \u2014 modelos en roedores de secci\u00f3n del tend\u00f3n de Aquiles, rotura del ligamento colateral medial y desgarro del manguito rotador (Chang et al., J Appl Physiol 2011; Staresinic et al., J Orthop Res 2003)<\/li>\n<li><strong>Gut barrier integrity and ulcer studies<\/strong> \u2014 modelos de \u00falcera g\u00e1strica, colitis y enfermedad inflamatoria intestinal; el origen g\u00e1strico del BPC-157 es relevante mec\u00e1nicamente aqu\u00ed (Sikiric et al., Curr Med Chem 2011)<\/li>\n<li><strong>Regeneraci\u00f3n del m\u00fasculo esquel\u00e9tico<\/strong> \u2014 post-injury recovery kinetics, myoblast proliferation, and myotube formation studies<\/li>\n<li><strong>Joint and cartilage studies<\/strong> \u2014 modelos de osteoartritis en roedores, composici\u00f3n de la matriz del cart\u00edlago, inflamaci\u00f3n sinovial<\/li>\n<li><strong>Angiog\u00e9nesis vascular<\/strong> \u2014 formaci\u00f3n de nuevos capilares y perfusi\u00f3n en sitios de tejido lesionado<\/li>\n<li><strong>Curaci\u00f3n \u00f3sea<\/strong> \u2014 fracture callus formation in osteotomy and bone-defect study models<\/li>\n<li><strong>Comparative recovery<\/strong> \u2014 comparativa con otros p\u00e9ptidos curativos, especialmente <a href=\"https:\/\/medsbase.com\/es\/tb-500\/\">TB-500 (Timosina Beta-4)<\/a> como el comparador sist\u00e9mico de curaci\u00f3n can\u00f3nico. Consulte la <a href=\"https:\/\/medsbase.com\/es\/bpc-157-vs-tb-500-comparison-guide\/\">comparaci\u00f3n BPC-157 vs TB-500<\/a> para ver una comparaci\u00f3n detallada.<\/li>\n<\/ul>\n<p>Para un contexto m\u00e1s amplio sobre d\u00f3nde encaja el BPC-157 en el panorama de los p\u00e9ptidos curativos, consulte <a href=\"https:\/\/medsbase.com\/es\/best-peptides-for-muscle-recovery\/\">los mejores p\u00e9ptidos para la recuperaci\u00f3n muscular<\/a> art\u00edculo del grupo y <a href=\"https:\/\/medsbase.com\/es\/ghk-cu\/\">el p\u00e9ptido de cobre GHK-Cu<\/a> as a complementary anti-aging compound. Browse the full <a href=\"https:\/\/medsbase.com\/es\/peptides\/\">cat\u00e1logo de p\u00e9ptidos<\/a> para compuestos relacionados. <\/p>\n<h2>Concentraciones y potencias disponibles<\/h2>\n<p>MedsBase ofrece BPC-157 en los siguientes tama\u00f1os de viales liofilizados. Cada variante se env\u00eda en paquetes de 10, 20 y 30 viales con instrucciones completas de reconstituci\u00f3n:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Potencia del vial<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de uso t\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tama\u00f1os de paquete<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>2 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Short protocols, pilot dosing, titration<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength, most commonly ordered<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Extended protocols, lowest per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All three strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Higher-mg vials require smaller reconstitution volumes per unit dose, which is useful when users want to minimise injection volume in rodent protocols. <\/p>\n<h2>C\u00f3mo se compara \u2014 BPC-157 vs TB-500<\/h2>\n<p>BPC-157 y <a href=\"https:\/\/medsbase.com\/es\/tb-500\/\">TB-500<\/a> are the two most-cited healing peptides. They are often studied in parallel because they act via complementary, largely non-overlapping mechanisms. Many preclinical protocols combine them rather than using either alone. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Criterio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">BPC-157<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">TB-500 (Timosina Beta-4)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Longitud<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">15 amino\u00e1cidos (pentadecap\u00e9ptido)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">43 amino\u00e1cidos (p\u00e9ptido t\u00edmico)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Mecanismo primario<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Regulaci\u00f3n al alza de VEGF + NO + receptor de GH<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Secuestro de G-actina, migraci\u00f3n celular<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Distribuci\u00f3n<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">M\u00e1s localizada en el lugar de la inyecci\u00f3n<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Sist\u00e9mica, se distribuye ampliamente<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dosis t\u00edpica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">250\u2013500 mcg, 1\u20132 veces al d\u00eda<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">2\u20132,5 mg, 2 veces por semana<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Strongest signal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Tend\u00f3n, ligamento, barrera intestinal<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Card\u00edaco, muscular sist\u00e9mico, vascular<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Combinaci\u00f3n<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Commonly co-administered with TB-500 in studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Commonly co-administered with BPC-157 in studies<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For a full methodological comparison including dosing protocols and when users pick one over the other, read <a href=\"https:\/\/medsbase.com\/es\/bpc-157-vs-tb-500-comparison-guide\/\">BPC-157 vs TB-500: qu\u00e9 p\u00e9ptido curativo para tu objetivo de recuperaci\u00f3n<\/a>. <\/p>\n<h2>Almacenamiento y reconstituci\u00f3n<\/h2>\n<p><strong>Antes de la reconstituci\u00f3n:<\/strong> almacene los viales liofilizados refrigerados a 2\u20138 \u00b0C en su envase original. El BPC-157 liofilizado es estable en estas condiciones hasta 36 meses. Evite ciclos de congelaci\u00f3n-descongelaci\u00f3n en el polvo. <strong>Procedimiento de reconstituci\u00f3n:<\/strong> inyecte agua bacteriost\u00e1tica por la pared lateral del vial de p\u00e9ptidos (no directamente sobre el polvo liofilizado) seg\u00fan la tabla de diluci\u00f3n anterior. Agite suavemente, no <strong>ajuste<\/strong> shake \u2014 and allow 2\u20135 minutes for full dissolution. A correctly reconstituted solution should be clear and colourless. <strong>Despu\u00e9s de la reconstituci\u00f3n:<\/strong> almacene refrigerado a 2\u20138 \u00b0C y utilice en 30 d\u00edas para una estabilidad \u00f3ptima. No congele la soluci\u00f3n reconstituida: los ciclos de congelaci\u00f3n-descongelaci\u00f3n degradan la integridad del p\u00e9ptido. Deseche cualquier vial que presente turbidez, precipitado o decoloraci\u00f3n. <\/p>\n<h2 id=\"faqs\">Preguntas frecuentes<\/h2>\n<h3>What is BPC-157 used for in studies?<\/h3>\n<p>BPC-157 is used in studies investigating tendon and ligament healing, gut barrier integrity, skeletal muscle recovery, vascular angiogenesis, anti-inflammatory signaling, and bone healing. It is <strong>ajuste<\/strong> FDA-approved and is sold here strictly for clinical studies use only. <\/p>\n<h3>\u00bfEn qu\u00e9 se diferencia el BPC-157 del TB-500?<\/h3>\n<p>BPC-157 is a 15-amino-acid pentadecapeptide derived from gastric juice, acting mostly locally via VEGF, nitric oxide, and growth-hormone-receptor pathways. TB-500 is a 43-amino-acid thymic peptide that acts systemically via G-actin binding and cell migration. The two are often co-administered in studies because their mechanisms are complementary rather than overlapping. <\/p>\n<h3>What is the typical BPC-157 dose?<\/h3>\n<p>Los protocolos precl\u00ednicos publicados suelen utilizar 250\u2013500 mcg por administraci\u00f3n, una o dos veces al d\u00eda durante ciclos de 4\u20138 semanas. Un vial de 5 mg reconstituido con 2,0 mL de agua bacteriost\u00e1tica produce 2,5 mg\/mL \u2014 10 divisiones en una jeringa U-100 equivalen a 250 mcg. <\/p>\n<h3>\u00bfEst\u00e1 aprobado el BPC-157 por la FDA?<\/h3>\n<p>No. BPC-157 is not approved by the FDA, EMA, MHRA, or any other regulator for human therapeutic use. <\/p>\n<h3>\u00bfC\u00f3mo se debe almacenar el BPC-157?<\/h3>\n<p>Viales liofilizados: refrigerados a 2\u20138 \u00b0C en su envase original, estables hasta 36 meses. Soluci\u00f3n reconstituida: refrigerada a 2\u20138 \u00b0C, usar en 30 d\u00edas. No congelar la soluci\u00f3n reconstituida \u2014 los ciclos de congelaci\u00f3n-descongelaci\u00f3n degradan el p\u00e9ptido. <\/p>\n<h3>\u00bfC\u00f3mo se reconstituye el BPC-157?<\/h3>\n<p>Siga la tabla de referencia de reconstituci\u00f3n anterior. A\u00f1ada agua bacteriost\u00e1tica por la pared lateral del vial (no directamente sobre el polvo liofilizado), agite suavemente y espere 2-5 minutos para su completa disoluci\u00f3n. No <strong>ajuste<\/strong> Agitar el vial. <\/p>\n<h3>\u00bfQu\u00e9 concentraciones tiene MedsBase en stock?<\/h3>\n<p>MedsBase ofrece BPC-157 en viales liofilizados de 2 mg, 5 mg y 10 mg. Cada concentraci\u00f3n est\u00e1 disponible en paquetes de 10, 20 o 30 viales. Todos los viales tienen una pureza HPLC del 99%+ y se proporciona certificado de an\u00e1lisis bajo petici\u00f3n. <\/p>\n<h3>Can BPC-157 and TB-500 be stacked in studies?<\/h3>\n<p>Yes. BPC-157 and TB-500 are frequently co-administered in preclinical studies because their mechanisms are complementary. BPC-157 acts mostly locally via growth-factor upregulation; TB-500 acts systemically via G-actin binding and cell migration. Combined protocols are described in our <a href=\"https:\/\/medsbase.com\/es\/bpc-157-vs-tb-500-comparison-guide\/\">gu\u00eda comparativa<\/a>. <\/p>\n<h3>Does BPC-157 cause side reported effects?<\/h3>\n<p>Published preclinical studies across rodent species has reported a notably clean safety profile at typical doses, with no consistent off-target signals and good tolerability. Long-term human safety data are not available because human trials have not been completed. <\/p>\n<h3>What is the difference between oral and injectable BPC-157 in studies?<\/h3>\n<p>BPC-157 is unusually stable in gastric acid due to its gastric-juice-derived origin, so oral administration is feasible in rodent protocols (unlike most peptides). Subcutaneous injection remains the most common administration route in the literature because it produces more reproducible plasma concentrations. <\/p>\n<h3>\u00bfCu\u00e1l es la semivida del BPC-157?<\/h3>\n<p>In preclinical studies, BPC-157 has an estimated plasma half-life of approximately 4 hours following subcutaneous administration. Oral route studies in rodent models suggest shorter systemic clearance but sustained local effects within the gastrointestinal tract, attributed to the peptide&#8217;s unusual acid-stability. <\/p>\n<h3>How long does BPC-157 take to show effects in preclinical studies?<\/h3>\n<p>Most preclinical studies using BPC-157 in tendon, ligament, and gut injury models report measurable tissue-level changes within 7\u201314 days. The time-course varies with the study model, injury severity, route of administration, and dose used in the study design. <\/p>\n<h3>\u00bfPuedo pedir BPC-157 para env\u00edo internacional?<\/h3>\n<p>S\u00ed. MedsBase env\u00eda BPC-157 a todo el mundo desde nuestra red de env\u00edos dedicada a p\u00e9ptidos. Los pedidos que contienen \u00fanicamente p\u00e9ptidos califican para nuestro servicio de env\u00edo exclusivo para p\u00e9ptidos. Todos los pedidos se env\u00edan en embalajes con control de temperatura y seguimiento completo. <\/p>\n<p class=\"medsbase-bundle-link-2026-05-01\" data-marker=\"mb-bundle-link-peptide-healing-stack\">Los protocolos de BPC-157 para la recuperaci\u00f3n de tendones, ligamentos y tejidos blandos suelen combinarlo con TB-500 para obtener efectos angiog\u00e9nicos + citoesquel\u00e9ticos sin\u00e9rgicos; para el r\u00e9gimen combinado, consulte nuestro <a href=\"\/es\/peptide-healing-stack\/\">Peptide Healing Stack (BPC-157 5 mg + TB-500 5 mg + agua bacteriost\u00e1tica)<\/a> con ambos viales liofilizados y agua de reconstituci\u00f3n en un mismo paquete a una tarifa de env\u00edo de p\u00e9ptidos de $0.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Recovery and Performance<\/h2>\n<ul>\n<li><a href=\"\/es\/tb-500\/\"><strong>TB-500<\/strong><\/a> \u2014 Thymosin Beta-4 fragment \u2014 soft tissue and vascular recovery<\/li>\n<li><a href=\"\/es\/ipamorelin\/\"><strong>Ipamorelina<\/strong><\/a> \u2014 Agonista selectivo de grelina \u2014 pulso de GH limpio sin cortisol\/prolactina<\/li>\n<li><a href=\"\/es\/cjc-1295-with-dac\/\"><strong>CJC-1295 con DAC<\/strong><\/a> \u2014 An\u00e1logo de GHRH con vida media extendida<\/li>\n<li><a href=\"\/es\/ghk-cu\/\"><strong>GHK-Cu<\/strong><\/a> \u2014 Copper peptide \u2014 skin and connective tissue regeneration<\/li>\n<li><a href=\"\/es\/igf-1-lr3\/\"><strong>IGF-1 LR3<\/strong><\/a> \u2014 Long-R3 IGF-1 analog \u2014 anabolic \/ regenerative support<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Lecturas adicionales<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Learn the science behind this peptide<\/strong><\/p>\n<p style=\"margin: 0;\">Lee nuestra gu\u00eda completa basada en evidencia: <a href=\"https:\/\/medsbase.com\/es\/bpc-157-peptide-healing-recovery-guide\/\"><strong>BPC-157 \u2014 mecanismo, datos de ensayos y perspectivas<\/strong><\/a>. Covers mechanism of action, published study data, typical dosing ranges, reconstitution protocols, stacking considerations, and safety\/contraindication notes.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Favorece la regeneraci\u00f3n celular<br \/>\n\u2705 Mejora el modelado tisular<br \/>\n\u2705 Promueve la actividad de los fibroblastos<br \/>\n\u2705 Estimula la se\u00f1alizaci\u00f3n angiog\u00e9nica<br \/>\n\u2705 Mejora la estabilidad de la matriz extracelular<\/p>\n<p><strong>BPC-157<\/strong> contiene compuesto de p\u00e9ptido sint\u00e9tico.<\/p>","protected":false},"featured_media":70942,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[5440,5430,5441],"class_list":["post-68745","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-bpc-157","product_tag-bpc-157-peptide","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product\/68745","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/comments?post=68745"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media\/70942"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media?parent=68745"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_brand?post=68745"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_cat?post=68745"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_tag?post=68745"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}